Investment case
C4 Therapeutics, Inc.
CCCC · 3 developments mapped · last assessed 2026-09-26
Market Ontology has mapped 3 macro, policy, and market developments to C4 Therapeutics, Inc. since 2026-09-26. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for CCCC yet, so no modelled value is shown. The CCCC valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run CCCC on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data
Positive clinical trial data for lead candidate, increasing probability of success and future revenue potential.
· Moves probability of technical success (pots), peak sales estimates, discount rate (reflecting reduced risk)
What changed, by assumption
- 2026-09-26C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data
- 2026-09-26C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS
- 2026-09-26C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-26 | C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data | Bullish | 1-3m | 0.80 |
| 2026-09-26 | C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS | Bullish | 1-3m | 0.80 |
| 2026-09-26 | C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data | Bullish | 1-3m | 0.80 |